Biotech Merger & Acquisition Due Diligence Training Course

Course Title: Biotech Merger & Acquisition Due Diligence Training Course

Executive Summary

This intensive two-week course equips participants with the knowledge and skills to effectively conduct due diligence in biotech mergers and acquisitions (M&A). The program covers critical areas such as scientific validation, intellectual property assessment, regulatory compliance, market analysis, and financial modeling specific to the biotech industry. Participants will learn to identify potential risks and opportunities associated with biotech M&A transactions, ensuring informed decision-making. Through real-world case studies, interactive workshops, and expert presentations, attendees will gain a comprehensive understanding of the unique challenges and complexities of biotech M&A due diligence, ultimately enhancing their ability to advise on and execute successful deals.

Introduction

Mergers and acquisitions in the biotechnology sector are complex, high-stakes transactions that require specialized due diligence expertise. Biotech companies possess unique characteristics, including cutting-edge science, intricate intellectual property portfolios, lengthy regulatory approval pathways, and volatile market conditions. A thorough and comprehensive due diligence process is crucial for identifying potential risks and uncovering hidden value in biotech M&A transactions. This course is designed to provide participants with a deep understanding of the key considerations and best practices for conducting effective due diligence in the biotech industry, covering scientific, legal, regulatory, commercial, and financial aspects. By attending this course, participants will be well-prepared to navigate the intricacies of biotech M&A and contribute to successful deal outcomes.

Course Outcomes

• Understand the specific challenges and complexities of biotech M&A due diligence.
• Assess the scientific validity and potential of biotech assets.
• Evaluate intellectual property portfolios and identify potential risks.
• Navigate regulatory landscapes and compliance requirements.
• Conduct market analysis and assess commercial viability.
• Perform financial modeling and valuation analysis.
• Identify potential risks and opportunities associated with biotech M&A transactions.

Training Methodologies

• Interactive expert-led lectures and presentations.
• Case study analysis of real-world biotech M&A deals.
• Group discussions and brainstorming sessions.
• Practical workshops on due diligence techniques.
• Guest lectures from experienced biotech M&A professionals.
• Role-playing exercises simulating due diligence scenarios.
• Q&A sessions with industry experts.

Benefits to Participants

• Gain a comprehensive understanding of biotech M&A due diligence best practices.
• Develop practical skills in assessing scientific, legal, regulatory, commercial, and financial aspects of biotech assets.
• Enhance your ability to identify potential risks and opportunities in biotech M&A transactions.
• Improve your decision-making skills in evaluating biotech deals.
• Expand your professional network with industry experts and peers.
• Receive a certificate of completion recognizing your expertise in biotech M&A due diligence.
• Increase your value to your organization as a skilled biotech M&A professional.

Benefits to Sending Organization

• Enhanced due diligence capabilities for biotech M&A transactions.
• Improved ability to identify and mitigate risks in biotech deals.
• Increased confidence in making informed investment decisions.
• Reduced potential for costly mistakes in biotech M&A.
• Strengthened competitive advantage in the biotech industry.
• Enhanced reputation as a sophisticated and knowledgeable player in biotech M&A.
• Improved return on investment in biotech M&A transactions.

Target Participants

• Corporate Development Professionals
• Venture Capital Investors
• Private Equity Professionals
• Investment Bankers
• Licensing and Business Development Executives
• Attorneys specializing in M&A and Biotech
• Consultants providing M&A advisory services

Week 1: Foundations of Biotech M&A Due Diligence

Module 1: Introduction to Biotech M&A

1. Overview of the biotech industry and M&A landscape.
2. Strategic rationale for biotech M&A deals.
3. Key players and deal structures in biotech M&A.
4. The role of due diligence in the M&A process.
5. Ethical considerations in biotech M&A.
6. Recent trends and developments in biotech M&A.
7. Case study: Analysis of a recent biotech M&A deal.

Module 2: Scientific Due Diligence

1. Understanding the scientific basis of biotech assets.
2. Evaluating preclinical and clinical data.
3. Assessing the validity of scientific claims.
4. Identifying potential scientific risks and limitations.
5. Working with scientific experts and consultants.
6. Interpreting scientific literature and reports.
7. Workshop: Evaluating a scientific data package.

Module 3: Intellectual Property Due Diligence

1. Overview of intellectual property rights in biotech.
2. Patent analysis and landscape assessment.
3. Freedom-to-operate analysis.
4. Identifying potential patent infringement risks.
5. Assessing the strength and enforceability of patents.
6. Evaluating trade secrets and confidential information.
7. Case study: IP due diligence in a biotech M&A deal.

Module 4: Regulatory Due Diligence

1. Overview of regulatory pathways for biotech products.
2. FDA approval process and requirements.
3. EMA approval process and requirements.
4. Assessing regulatory compliance and risks.
5. Evaluating manufacturing and quality control processes.
6. Understanding regulatory exclusivity and market protection.
7. Workshop: Navigating the FDA website and databases.

Module 5: Commercial Due Diligence

1. Market analysis and competitive landscape assessment.
2. Evaluating market size and growth potential.
3. Assessing commercial viability and pricing strategies.
4. Identifying potential market access barriers.
5. Analyzing sales and marketing data.
6. Understanding reimbursement and payer dynamics.
7. Case study: Commercial due diligence in a biotech M&A deal.

Week 2: Advanced Due Diligence and Deal Execution

Module 6: Financial Due Diligence

1. Overview of financial statements and accounting principles.
2. Analyzing revenue and expense trends.
3. Evaluating profitability and cash flow.
4. Assessing working capital and debt levels.
5. Identifying potential financial risks and liabilities.
6. Performing financial modeling and valuation analysis.
7. Workshop: Building a financial model for a biotech company.

Module 7: Valuation in Biotech M&A

1. Overview of valuation methods for biotech companies.
2. Discounted cash flow (DCF) analysis.
3. Comparable company analysis.
4. Precedent transaction analysis.
5. Risk-adjusted net present value (rNPV) analysis.
6. Real options analysis.
7. Case study: Valuing a biotech company in an M&A deal.

Module 8: Legal Due Diligence

1. Reviewing contracts and agreements.
2. Assessing litigation risks and liabilities.
3. Evaluating corporate governance and compliance.
4. Identifying potential environmental and regulatory liabilities.
5. Understanding employment law and employee benefits.
6. Analyzing tax implications of the transaction.
7. Case study: Legal due diligence in a biotech M&A deal.

Module 9: Deal Negotiation and Documentation

1. Negotiation strategies and tactics in biotech M&A.
2. Key terms and provisions in M&A agreements.
3. Representations and warranties.
4. Indemnification clauses.
5. Closing conditions.
6. Material adverse change (MAC) clauses.
7. Workshop: Negotiating a biotech M&A agreement.

Module 10: Post-Merger Integration

1. Planning for post-merger integration.
2. Integrating scientific research and development teams.
3. Harmonizing intellectual property portfolios.
4. Integrating regulatory compliance systems.
5. Aligning sales and marketing strategies.
6. Managing cultural differences.
7. Case study: Post-merger integration challenges in biotech.

Action Plan for Implementation

1. Conduct a thorough assessment of your current biotech M&A due diligence processes.
2. Identify areas for improvement and develop a prioritized action plan.
3. Implement training programs to enhance the skills of your team.
4. Develop standardized due diligence checklists and templates.
5. Establish clear communication channels and reporting mechanisms.
6. Monitor the effectiveness of your due diligence processes and make adjustments as needed.
7. Continuously stay informed of the latest trends and developments in biotech M&A.